Baseline characteristics of MSK cohort
| Characteristic . | Full Cohort (n = 151) . |
|---|---|
| Age at diagnosis (in y) | |
| Median (range) | 54 (21-71) |
| Male | 83/151 (55%) |
| Female | 68/151 (45%) |
| LDH > ULN | 120/151 (79%) |
| KPS ≤ 70% | 52/151 (34%) |
| Stage II | 10/151 (7%) |
| Stage III-IV | 141/151 (93%) |
| Extranodal sites > 1 | 81/151 (54%) |
| Bone marrow biopsy + | 40/151 (26%) |
| aaIPI score | |
| LIR | 27/151 (18%) |
| HIR | 86/151 (57%) |
| HR | 38/151 (25%) |
| Bulk > 10 cm | 32/151 (21%) |
| COO GCB | 69/151 (46%) |
| Non-GCB | 69/151 (46%) |
| Unclassified | 13/151 (9%) |
| Characteristic . | Full Cohort (n = 151) . |
|---|---|
| Age at diagnosis (in y) | |
| Median (range) | 54 (21-71) |
| Male | 83/151 (55%) |
| Female | 68/151 (45%) |
| LDH > ULN | 120/151 (79%) |
| KPS ≤ 70% | 52/151 (34%) |
| Stage II | 10/151 (7%) |
| Stage III-IV | 141/151 (93%) |
| Extranodal sites > 1 | 81/151 (54%) |
| Bone marrow biopsy + | 40/151 (26%) |
| aaIPI score | |
| LIR | 27/151 (18%) |
| HIR | 86/151 (57%) |
| HR | 38/151 (25%) |
| Bulk > 10 cm | 32/151 (21%) |
| COO GCB | 69/151 (46%) |
| Non-GCB | 69/151 (46%) |
| Unclassified | 13/151 (9%) |
aaIPI, age-adjusted International Prognostic Index; COO, cell of origin; GCB, germinal center B-cell like; HIR, high-intermediate risk; HR, high risk; KPS, Karnofsky Performance Status; LDH, lactate dehydrogenase; LIR, low-intermediate risk; MSK, Memorial Sloan Kettering; ULN, upper limit of normal.